Prostate Protocol

We have joined a national study sponsored by Accuray enrolling patients with Low Risk (CS T1b-T2a, Gleason ≤ 6 & PSA ≤ 10) and Intermediate Risk (CS T2b, Gleason ≤ 6 & PSA ≤ 10 or CS T1b-T2a, Gleason = 7 & PSA ≤ 10, or Gleason ≤ 6 & PSA > 10 & ≤ 20) prostate cancer for CyberKnife radiosurgery. The treatment consists of 4 fractions of high-dose radiation delivering a total of 38Gy. Early single institution studies demonstrated biochemical control of over 95%.

Please call our office at (626) 768-1021 if you would like to enroll patients onto this protocol.